Overview
Gmt Id is the creator of a mobile platform for genetic diagnostics called Genomtec ID, designed for point-of-care testing. The company has obtained a CE-IVD Mark for its GenomtecID Respiratory Panel 5-Plex, which detects viruses and bacteria responsible for respiratory tract infections, making it the only solution of its kind in Europe. Additionally, Genomtec is preparing for technology trials in Asia as part of its ongoing M&A efforts.
Financials
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
News
Miron Tokarski to appear in upcoming webinar “Meeting the Challenges and Unlocking the Potential of Point-of-Care Molecular Diagnostics”
Another patent granted. Another step in building global protection of Genomtec molecular diagnostics technology
Genomtec secured PLN 11 million from share issue for finalizing global M&A strategy and commercialization of breakthrough Genomtec ID and OncoSNAAT® technologies
Start of Genomtec public share offering to raise funds for finalizing M&A process and commercialization of Genomtec ID and OncoSNAAT® technologies
Genomtec plans share issue. Funds will support M&A process and project commercialization. Company signed investment agreement with key shareholder.
Genomtec prepares to test its technology with potential partners in Asia as part of M&A process
Industry
Bank accounts
Registered as a VAT taxpayer on 2025-11-01. Active
09 1090 2398 0000 0001 6186 7103- 21 1090 2398 0000 0001 6186 7081
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
Public aid
No public aid cases recorded in the last 10 years.
European Funds
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2020-10-15 | Opracowanie mobilnej aparatury diagnostycznej bazującej na rozwiązaniu lab-on-chip do wykrywania choroby COVID-19 (SARS-CoV-2 wirus) | $1.7M$1,651,274 | Program Operacyjny Inteligentny Rozwój | |
| 2019-01-01 | Opracowanie technologii oraz mobilnej aparatury diagnostycznej bazującej na rozwiązaniu lab-on-chip do wykrywania chorób zakaźnych | $2.3M$2,282,737 | Program Operacyjny Inteligentny Rozwój |
Tenders
No recorded participation in tenders.
Authorized Representatives
Manner of representation
The company is represented by each member of the management board independently.
Supervisory board
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
| 600,000 | $162,074.55 | 100% | |
| — | — | 0% |
Beneficial owners
| Person | Rights | |
|---|---|---|
Miron Tokarski (36)  | Natural person holding a senior management position (AML Act art. 2(2)(1)(a) indent 5). | |
Miron Tokarski (36) | Natural person holding a senior management position in a parent entity (e.g. parent company). | |
Michał Wachowski (44) | Natural person holding a senior management position (AML Act art. 2(2)(1)(a) indent 5). | |
Michał Wachowski (44) | Natural person holding a senior management position in a parent entity (e.g. parent company). |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| GenomedS.A. | $7,373,750.46 | genomed.pl | ||
| IntodnaS.A. | $2,286,118.76 | intodna.com | ||
| Read-GeneS.A. | $2,163,474.84 | read-gene.com | ||
| MedisensonicS.A. | $362,572.63 | medisensonic.com | ||
| ETG Zamośćsp. z o.o. | $260,151.02 | etg-network.com | ||
| Vitrotest Europesp. z o.o. | $233,350.77 | vitrotest.pl | ||
| GenomtecS.A. | $47,965.85 | genomtec.com | ||
| Advanced Diagnostic Equipmentsp. z o.o. | $43,171.56 | adediabetics.pl | ||
| Micropurasp. z o.o. | $12,556.50 | micropura.eu | ||
| Vitagenumsp. z o.o. | $9,376.94 | vitagenum.pl |
Change history
| Date | Event | |
|---|---|---|
| 2026-05-11 | Share capital change (100,000.00 PLN → 600,000.00 PLN) | |
| 2025-05-21 | Entered in the register |
FAQ
Last updated: 2026-09-15